{"title":"Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia","authors":"K. Maki, S. Poulos, Alyssa K Phillips, A. Lawless","doi":"10.2217/clp.14.39","DOIUrl":null,"url":null,"abstract":"Abstract The role of omega-3 (OM3) fatty acids in the reduction of elevated triglycerides is well recognized. This has prompted the development of concentrated OM3 drugs for the treatment of hypertriglyceridemia, a condition that may increase risk for cardiovascular disease and pancreatitis. Intestinal absorption of currently available OM3 ethyl ester drugs depends on the activity of pancreatic lipases, largely stimulated by dietary fat. As many patients with severe hypertriglyceridemia are advised to minimize fat intake, there is a need for a product with high bioavailability, irrespective of meal timing and fat content. This review will discuss a novel OM3 carboxylic acid drug (Epanova®, AstraZeneca, DE, USA) that has been approved as an adjunct to diet for the treatment of severe hypertriglyceridemia.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"41 1","pages":"399 - 406"},"PeriodicalIF":0.0000,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.14.39","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3
Abstract
Abstract The role of omega-3 (OM3) fatty acids in the reduction of elevated triglycerides is well recognized. This has prompted the development of concentrated OM3 drugs for the treatment of hypertriglyceridemia, a condition that may increase risk for cardiovascular disease and pancreatitis. Intestinal absorption of currently available OM3 ethyl ester drugs depends on the activity of pancreatic lipases, largely stimulated by dietary fat. As many patients with severe hypertriglyceridemia are advised to minimize fat intake, there is a need for a product with high bioavailability, irrespective of meal timing and fat content. This review will discuss a novel OM3 carboxylic acid drug (Epanova®, AstraZeneca, DE, USA) that has been approved as an adjunct to diet for the treatment of severe hypertriglyceridemia.
omega-3 (OM3)脂肪酸在降低甘油三酯升高中的作用是公认的。这促使了用于治疗高甘油三酯血症(一种可能增加心血管疾病和胰腺炎风险的疾病)的浓缩OM3药物的开发。目前可用的OM3乙酯类药物的肠道吸收取决于胰腺脂肪酶的活性，主要由膳食脂肪刺激。由于许多患有严重高甘油三酯血症的患者被建议尽量减少脂肪摄入，因此需要一种生物利用度高的产品，无论进餐时间和脂肪含量如何。本综述将讨论一种新的OM3羧酸药物(Epanova®，AstraZeneca, DE, USA)，该药物已被批准作为饮食辅助治疗严重高甘油三酯血症。
期刊介绍：
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
